Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediatric and Adolescent Subjects (Aged 4 to 16 Years) With an Acute Exacerbation of Asthma
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Asthma and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .